Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes Track

A new octadentate chelator for the rapid complexation of 89Zr.

Christian Buchwalder, Katayoun Saatchi, Paul Schaffer and Urs Häfeli
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1098;
Christian Buchwalder
2Faculty of Pharmaceutical Sciences University of British Columbia Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katayoun Saatchi
2Faculty of Pharmaceutical Sciences University of British Columbia Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Schaffer
1TRIUMF Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Urs Häfeli
2Faculty of Pharmaceutical Sciences University of British Columbia Vancouver BC Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1098

Objectives Zirconium-89 is a prominent radionuclide for immuno-PET as its physical half-life matches the biological half-life of antibodies well and its emission properties are suited for PET imaging. The currently available gold standard chelator for 89Zr, desferrioxamine (DFO), shows stability deficits that result in bone uptake. Herein we report an alternative octadentate chelator that can bind 89Zr under mild radiolabeling conditions.

Methods We synthesized a new acyclic octadentate chelator that is based on four 3-hydroxy-4-pyridinone (3,4-HOPO) units and studied its complexation potential with natZr(IV). Complex formation was characterized using mass spectrometry, NMR-, FT-IR-, and UV-Vis spectroscopy. The kinetics and complexation yield were then studied with 89Zr at room temperature and different pH conditions using radio-TLC and radio-HPLC.

Results The chelator was found to quantitatively complex 89Zr within 15 min at room temperature and neutral pH (6.5-7.5). At lower pH values slower radiolabeling kinetics were observed. Mass spectrometry indicated the formation of the 1:1 metal:ligand complex. The complex formation was also observed by a redshift of the UV-Vis absorption maximum from 282 to 302 nm, shifts in the FT-IR absorption bands, as well as a loss of symmetry as observed via the 1H-NMR spectrum.

Conclusions The novel chelator was found to be a promising candidate for the complexation of 89Zr. It provides efficient radiolabeling at room temperature and neutral pH within 15 min. The monometallic complex was characterized using different analytical techniques. The rapid complex formation at room temperature is interesting for the compatibility with large molecular weight biomolecules such as antibodies. We are in the process of assessing the complex stability by transchelation challenge experiments and biodistribution in vivo. Further studies are focused on a bifunctional version of the chelator for immuno-PET.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 57, Issue supplement 2
May 1, 2016
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
A new octadentate chelator for the rapid complexation of 89Zr.
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
A new octadentate chelator for the rapid complexation of 89Zr.
Christian Buchwalder, Katayoun Saatchi, Paul Schaffer, Urs Häfeli
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1098;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A new octadentate chelator for the rapid complexation of 89Zr.
Christian Buchwalder, Katayoun Saatchi, Paul Schaffer, Urs Häfeli
Journal of Nuclear Medicine May 2016, 57 (supplement 2) 1098;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes Track

  • Synthesis and preliminary biological evaluation of a novel P2X7R radioligand [18F]IUR-1601
  • In vivo evaluation of [225Ac]Ac-DOTAZOL for α-therapy of bone metastases
  • Case study: Evaluating the new University of Florida hybrid pediatric phantoms and tissue weighting factors from ICRP Publication 103 for diagnostic dosimetry
Show more Molecular Targeting Probes Track

SPECIAL MTA: Novel Radiochemistry & Chelation Posters

  • Radiolabeling, Characterization and Biodistribution study of Cysteine and its derivatives with Tc99m.
  • Radiolabeling and biological evaluations of N-methylated 76Br and 123I labeled amino acids for imaging of brain tumors
  • Catalytic Asymmetric 11C-Labeling of Native Tetrapeptide D-[11C]-Phe-D-Trp-L-Lys-L-Thr-OH as the Essential Pharmacophore for Somatostatin Imaging
Show more SPECIAL MTA: Novel Radiochemistry & Chelation Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire